Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $18.29 million. The enterprise value is $6.97 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 48.14 million shares outstanding. The number of shares has increased by 6.53% in one year.
| Current Share Class | 48.14M |
| Shares Outstanding | 48.14M |
| Shares Change (YoY) | +6.53% |
| Shares Change (QoQ) | +3.31% |
| Owned by Insiders (%) | 5.47% |
| Owned by Institutions (%) | 15.26% |
| Float | 45.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.10 |
| Forward PS | 20.29 |
| PB Ratio | 0.34 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.12, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.12 |
| Quick Ratio | 3.66 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.40% and return on invested capital (ROIC) is -41.11%.
| Return on Equity (ROE) | -63.40% |
| Return on Assets (ROA) | -38.09% |
| Return on Invested Capital (ROIC) | -41.11% |
| Return on Capital Employed (ROCE) | -90.64% |
| Revenue Per Employee | $7,603 |
| Profits Per Employee | -$272,659 |
| Employee Count | 132 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.48 |
Taxes
In the past 12 months, Co-Diagnostics has paid $38,345 in taxes.
| Income Tax | 38,345 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.31% in the last 52 weeks. The beta is 0.94, so Co-Diagnostics's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -70.31% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 52.07 |
| Average Volume (20 Days) | 14,492,355 |
Short Selling Information
The latest short interest is 795,088, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 795,088 |
| Short Previous Month | 1.36M |
| Short % of Shares Out | 1.65% |
| Short % of Float | 1.75% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $1.00 million and -$35.99 million in losses. Loss per share was -$1.14.
| Revenue | 1.00M |
| Gross Profit | 397,486 |
| Operating Income | -38.75M |
| Pretax Income | -35.95M |
| Net Income | -35.99M |
| EBITDA | -37.47M |
| EBIT | -38.75M |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $13.36 million in cash and $1.70 million in debt, giving a net cash position of $11.66 million or $0.24 per share.
| Cash & Cash Equivalents | 13.36M |
| Total Debt | 1.70M |
| Net Cash | 11.66M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 41.14M |
| Book Value Per Share | 1.14 |
| Working Capital | 11.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.49 million and capital expenditures -$740,403, giving a free cash flow of -$33.23 million.
| Operating Cash Flow | -32.49M |
| Capital Expenditures | -740,403 |
| Free Cash Flow | -33.23M |
| FCF Per Share | -$0.69 |
Full Cash Flow StatementMargins
| Gross Margin | 39.60% |
| Operating Margin | -3,861.06% |
| Pretax Margin | -3,582.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.53% |
| Shareholder Yield | -6.53% |
| Earnings Yield | -193.23% |
| FCF Yield | -178.42% |
Analyst Forecast
The average price target for Co-Diagnostics is $2.00, which is 426.32% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.00 |
| Price Target Difference | 426.32% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 175.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of -0.9 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.9 |
| Piotroski F-Score | 1 |
